Plasmozytom: Studien
| Gruppe | Studie | Arm | % CR | PFS | RR für Progress oder Tod | Bemerkungen |
| Lenalidomid-Studien | TOURMALINE-MM1 | Lenalidomid–Dexamethason | 7 | 14.7 | 0.74 (0.59–0.94) | 0.01 |
| Ixazomib– Lenalidomid–Dexamethason | 12 | 20.6 | ||||
| ELOQUENT-2 | Lenalidomid–Dexamethason | 7 | 14.9 | 0.70 (0.57–0.85) | <0.001 | |
| Elotuzumab– Lenalidomid–Dexamethason | 4 | 19.4 | ||||
| ASPIRE | Lenalidomid–Dexamethason | 14 | 17.6 | 0.69 (0.57–0.83) | <0.001 | |
| Carfilzomib– Lenalidomid–Dexamethason | 32 | 26.3 | ||||
| POLLUX | Lenalidomid–Dexamethason | 19 | 18.4 | 0.37 (0.27–0.52) | <0.001 | |
| Daratumumab– Lenalidomid–Dexamethason | 43 | NR | ||||
| Bortezomib-Studien | PANORAMA1 | Bortezomib–Dexamethason | 6 | 8.1 | 0.63 (0.52–0.76) | <0.001 |
| Panobinostat–Bortezomib–Dexamethason | 11 | 12.0 | ||||
| CASTOR | Bortezomib–Dexamethason | 9 | 7.2 | 0.39 (0.28–0.53) | <0.001 | |
| Daratumumab–Bortezomib–Dexamethason | 19 | NR | ||||
| CAR–T-cell therapy | CARTIFAN-1 | Ciltacabtagene Autoleucel Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor–T-Cell Therapy | ||||
Proteasom-IH
Carfilzumib verlängert in der Kombination mit Lenalidomid und Dexamethason das rezidivfreie Überleben und die Überlebensrate rezidivierter multipler Myelomene!
ENDEAVOR
| POLLUX | Daratumumab, Lenalidomid, and Dexamethasone for Multiple Myeloma |
| CASTOR | Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma |
| ALCYONE | Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma |
| PERSEUS | Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma (9) |
| IMROZ | Isatuximab, Bortezomib, Lenalidomide, Dexamethasone (unbehandeltes MM) (10) |
| MM-015-Studie | Lenalidomid nach Stammzell Transplantation bei multiplem Myelom. |
| RV-MM-PI-209 (7) | GIMEMA: A Phase III, Multicenter, randomized, Controlled Study to Determine the Efficacy and Safety of Lenalidomide, Melphalan, and Prednisone Versus Melphalan (200 mg/m2) Followed by Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma. |
| IFM 2005-02 (8) | Relevance of Maintenance Therapy Using Lenalidomide After Autologous Stem Cell Transplantation Patients Under the Age of 65. |
Bortezomib - Induktion, VAD, Erhaltung mit Bortezomib versus Thalidomid.
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma (2)
Phase III - Studie: Konventionelle Chemotherapie gefolgt von einer Hochdosistherapie und Transplantation autologer peripherer Progenitorzellen vs. alleiniger konventionelle Chemotherapie bei älteren Patienten (65-75 Jahren) mit Multiplem Myelom
Lenalidomid + Dexa versus Melphalan, Prednisolon, Thalidomid bei multiplem Myelom > 65a.
Registerstudie
Bortezomib, Melphalan, Prednison
Gruppo Italiano Malattie Ematologiche dell’Adulto
Programa Español de Tratamientos en Hematología
European Group for Blood and Marrow Transplantation. Deutlichen Vorteil der allogenen SCT (Einsele, Würzburg, ASCO 2011).
Deutschen Studiengruppe multiples Myelom. Allogener SCT kombiniert mit neuen Substanzen verbessern die Tumorkontrolle.
Melphalan, Prednison +- Thalidomid
Melphalan, Prednison +- Thalidomid bei multiplem Myelom >75a
Teil von
1.) Dimopoulos MA, et al:
Risk factors for, and reversibility of, peripheral neuropathy associated with
bortezomib-melphalan prednisone in newly diagnosed patients with multiple
myeloma: Subanalysis of the phase 3 VISTA study.
Eur J Haematol 86(2011):23-31
2.) Moreau P, et al. for the TOURMALINE-MM1 Study Group:
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med 2016;374:1621-34. DOI: 10.1056/NEJMoa1516282
3.) Rajkumar SV, Kyle RA:
Progress in Myeloma — A Monoclonal Breakthrough.
N Engl J Med 2016;375:1390-1392
4.) San Miguel JF, Schlag R, Khuageva NK, et al.:
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
N Engl J Med 2008; 359: 906-17.
5.) Palumbo A, Bringhen S, Rossi D, et al.:
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma:
a randomized controlled trial.
J Clin Oncol 2010; 28: 5101-9.
6.) Mateos MV, Oriol A, Martínez-López J, et al.:
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy
followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma:
a randomised trial.
Lancet Oncol 2010; 11: 934-41.
7.) Palumbo A, Cavallo F, Gay F, et al.:
Autologous transplantation and maintenance therapy in multiple myeloma.
N Engl J Med 2014;371:895-905
8.) Attal M, Lauwers-Cances V, Marit G, et al.:
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
N Engl J Med 2012;366:1782-1791
9.) Sonneveld P, et al. for the PERSEUS Trial Investigators:
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med 2024;390:301-13.
DOI: 10.1056/NEJMoa2312054
10.) Facon, T, et al. for the IMROZ Study Group:
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med 2024;391:1597-609.
DOI: 10.1056/NEJMoa2400712
